These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 30120496)
1. Age-corrected hearing loss after chemoradiation in cervical cancer patients. Marnitz S; Schermeyer L; Dommerich S; Köhler C; Olze H; Budach V; Martus P Strahlenther Onkol; 2018 Nov; 194(11):1039-1048. PubMed ID: 30120496 [TBL] [Abstract][Full Text] [Related]
2. Prediction of Hearing Loss Due to Cisplatin Chemoradiotherapy. Theunissen EA; Zuur CL; Józwiak K; Lopez-Yurda M; Hauptmann M; Rasch CR; van der Baan S; de Boer JP; Dreschler WA; Balm AJ JAMA Otolaryngol Head Neck Surg; 2015 Sep; 141(9):810-5. PubMed ID: 26291150 [TBL] [Abstract][Full Text] [Related]
3. A new grading system for ototoxicity in adults. Theunissen EA; Dreschler WA; Latenstein MN; Rasch CR; van der Baan S; de Boer JP; Balm AJ; Zuur CL Ann Otol Rhinol Laryngol; 2014 Oct; 123(10):711-8. PubMed ID: 24820112 [TBL] [Abstract][Full Text] [Related]
4. Audiometric patterns in ototoxicity of intra-arterial Cisplatin chemoradiation in patients with locally advanced head and neck cancer. Zuur CL; Simis YJ; Lansdaal PE; Rasch CR; Tange RA; Balm AJ; Dreschler WA Audiol Neurootol; 2006; 11(5):318-30. PubMed ID: 16983183 [TBL] [Abstract][Full Text] [Related]
5. Long-term hearing loss after chemoradiation in patients with head and neck cancer. Theunissen EA; Zuur CL; Bosma SC; Lopez-Yurda M; Hauptmann M; van der Baan S; de Boer JP; van der Molen L; Rasch CR; Dreschler WA; Balm AJ Laryngoscope; 2014 Dec; 124(12):2720-5. PubMed ID: 24964759 [TBL] [Abstract][Full Text] [Related]
6. Development and validation of a cisplatin dose-ototoxicity model. Dille MF; Wilmington D; McMillan GP; Helt W; Fausti SA; Konrad-Martin D J Am Acad Audiol; 2012; 23(7):510-21. PubMed ID: 22992258 [TBL] [Abstract][Full Text] [Related]
7. Comprehensive Audiometric Analysis of Hearing Impairment and Tinnitus After Cisplatin-Based Chemotherapy in Survivors of Adult-Onset Cancer. Frisina RD; Wheeler HE; Fossa SD; Kerns SL; Fung C; Sesso HD; Monahan PO; Feldman DR; Hamilton R; Vaughn DJ; Beard CJ; Budnick A; Johnson EM; Ardeshir-Rouhani-Fard S; Einhorn LH; Lipshultz SE; Dolan ME; Travis LB J Clin Oncol; 2016 Aug; 34(23):2712-20. PubMed ID: 27354478 [TBL] [Abstract][Full Text] [Related]
8. Feasibility and acute toxicity of Concurrent Chemoradiotherapy (CCRT) with high-dose rate intracavitary brachytherapy (HDR-ICBT) and 40-mg/m2 weekly cisplatin for Japanese patients with cervical cancer: results of a Multi-Institutional Phase 2 Study (JGOG1066). Toita T; Kitagawa R; Hamano T; Umayahara K; Hirashima Y; Aoki Y; Oguchi M; Mikami M; Takizawa K; Int J Gynecol Cancer; 2012 Oct; 22(8):1420-6. PubMed ID: 22932262 [TBL] [Abstract][Full Text] [Related]
9. [Monitoring hearing during ototoxic cisplatin therapy]. Kluba J; Kluba U; von Specht H; Mittler U Padiatr Grenzgeb; 1990; 29(1):19-23. PubMed ID: 2342815 [TBL] [Abstract][Full Text] [Related]
10. Relative contributions of radiation and cisplatin-based chemotherapy to sensorineural hearing loss in head-and-neck cancer patients. Das N; Kaushal D; Patro SK; Pareek P; Dixit A; Soni K; Prakasan Nair N; Choudhury B; Goyal A Acta Otolaryngol; 2021 Sep; 141(9):885-893. PubMed ID: 34486907 [TBL] [Abstract][Full Text] [Related]
11. Impact of radiation technique, radiation fraction dose, and total cisplatin dose on hearing : Retrospective analysis of 29 medulloblastoma patients. Scobioala S; Parfitt R; Matulat P; Kittel C; Ebrahimi F; Wolters H; Am Zehnhoff-Dinnesen A; Eich HT Strahlenther Onkol; 2017 Nov; 193(11):910-920. PubMed ID: 28887665 [TBL] [Abstract][Full Text] [Related]
12. Ototoxicity in a randomized phase III trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer. Zuur CL; Simis YJ; Lansdaal PE; Hart AA; Schornagel JH; Dreschler WA; Rasch CR; Balm AJ J Clin Oncol; 2007 Aug; 25(24):3759-65. PubMed ID: 17704425 [TBL] [Abstract][Full Text] [Related]
13. Hearing loss due to concurrent daily low-dose cisplatin chemoradiation for locally advanced head and neck cancer. Zuur CL; Simis YJ; Verkaik RS; Schornagel JH; Balm AJ; Dreschler WA; Rasch CR Radiother Oncol; 2008 Oct; 89(1):38-43. PubMed ID: 18706728 [TBL] [Abstract][Full Text] [Related]
14. Long-term ototoxicity in women after cisplatin treatment for ovarian germ cell cancer. Skalleberg J; Solheim O; Fosså SD; Småstuen MC; Osnes T; Gundersen POM; Bunne M Gynecol Oncol; 2017 Apr; 145(1):148-153. PubMed ID: 28202195 [TBL] [Abstract][Full Text] [Related]
16. Chemoradiation-induced hearing loss remains a major concern for head and neck cancer patients. Schmitt NC; Page BR Int J Audiol; 2018 Sep; 57(sup4):S49-S54. PubMed ID: 28728452 [TBL] [Abstract][Full Text] [Related]
17. Sensorineural hearing loss following induction chemotherapy plus concurrent chemoradiotherapy for advanced nasopharyngeal carcinoma. Atchariyasathian V; Pruegsanusak K; Wongsriwattanakul S J Laryngol Otol; 2015 Aug; 129(8):767-72. PubMed ID: 26112091 [TBL] [Abstract][Full Text] [Related]
18. Auditory function and quality of life in patients receiving cisplatin chemotherapy in head and neck cancer: A case series follow-up study. Kalyanam B; Sarala N; Azeem Mohiyuddin SM; Diwakar R J Cancer Res Ther; 2018; 14(5):1099-1104. PubMed ID: 30197356 [TBL] [Abstract][Full Text] [Related]
19. Progressive hearing loss after completion of cisplatin chemotherapy is common and more pronounced in children without spontaneous otoacoustic emissions before chemotherapy. Weissenstein A; Deuster D; Knief A; Zehnhoff-Dinnesen AA; Schmidt CM Int J Pediatr Otorhinolaryngol; 2012 Jan; 76(1):131-6. PubMed ID: 22104469 [TBL] [Abstract][Full Text] [Related]
20. [Hearing assessment of children treated with Cisplatin]. Mniszek J; Bielecki I; Sobol G Pol Merkur Lekarski; 2009 Aug; 27(158):105-8. PubMed ID: 19856874 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]